Online inquiry

IVTScrip™ mRNA-Anti-HGF, AMG 102(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ2370MR)

This product GTTS-WQ2370MR is a type of mRNA modified with N1-Methylpseudo-UTP, which ecodes the monoclonal antibody that targets HGF gene. The antibody can be applied in Gastric Cancer research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000601.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3082
UniProt ID P14210
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-HGF, AMG 102(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ2370MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ13094MR IVTScrip™ mRNA-Anti-ACVRL1, PF-03446962(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA PF-03446962
GTTS-WQ5888MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, CIFN(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CIFN
GTTS-WQ14259MR IVTScrip™ mRNA-Anti-ERBB3, RG-7116(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA RG-7116
GTTS-WQ9560MR IVTScrip™ mRNA-Anti-TNFRSF17, J6M0(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA J6M0
GTTS-WQ10291MR IVTScrip™ mRNA-Anti-PCSK9, LGT209(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA LGT209
GTTS-WQ1929MR IVTScrip™ mRNA-Anti-VEGFA, AGN 150998(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AGN 150998
GTTS-WQ14265MR IVTScrip™ mRNA-Anti-ERBB3, RG-7116(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA RG-7116
GTTS-WQ13670MR IVTScrip™ mRNA-Anti-TNFSF13B, RC18(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA RC18
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW